HALIFAX, May 28 – MedMira Inc., (“MedMira”) (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, announced today that VWR International, LLC (VWR) has joined the Company’s U.S. distribution network. Headquartered in West Chester, Pennsylvania, VWR is a global laboratory supply and distribution company with worldwide sales in excess of $3.7 billion.

“The U.S. is an important market for MedMira and building out our distribution network is a key initiative in maintaining and expanding our market position. Adding VWR to our U.S. distribution network will increase our sales revenues and enable us to fully capitalize on opportunities to launch new products in the market,” said Hermes Chan, CEO, MedMira. “VWR will work with MedMira’s U.S.-based sales and marketing partner American Health Diagnostics (AHD) to expand sales for our Reveal G3 rapid HIV test and identify opportunities for new MedMira products.”

“We provide our customers with the most innovative products available on the market today. Adding MedMira’s 3-minute rapid HIV test to our product portfolio will provide our U.S. customers with a critical diagnostic tool,” said Mark McLoughlin, Senior Vice President, Category Management North America, VWR.

About MedMira

MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company’s tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company’s tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira’s rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira’s website at www.medmira.com.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company’s current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

The TSX Venture Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of this statement.

SOURCE MEDMIRA INC.